Regulation And Legal
Aurobindo Pharma Subsidiary Receives 2 US FDA Observations
Aurobindo Pharma discloses US FDA inspection at its wholly-owned API subsidiary Auroactive Pharma from June 22-26, 2026.
The inspection concluded with 2 observations, which the company will respond to
